DCC-2618, a pan-KIT and PDGFRA switch control inhibitor, achieves proof-of-concept in a first-in-human study.

Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor.

Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors. ASCO 2017 Annual Meeting, Chicago, Il. Abstract# 2515

Thresholds for Meaningful Change for the EQ-5D VAS and EORTC QLQ-C30 Physical and Role Functioning Scale in Gastrointestional-Related Cancers

The INVICTUS Trial: Ripretinib As ≥4th-Line Therapy In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

DCC-2618, a novel pan-KIT and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST). 

DCC-2618, a novel pan-KIT and PDGFRα kinase switch control inhibitor, shows encouraging signal in a patient with glioblastoma (GBM).

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Pharmacokinetic (PK), Safety, and Tolerability Profile of DCC-2618 in a Phase 1 Clinical Trial Supports 150mg QD Selected for a Pivotal Phase 3 Study in Gastrointestinal Stromal Tumor (GIST). 

Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618.